Citi Initiates DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Announces Target Price $48.4
Jefferies Maintains DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Cuts Target Price to $45.63
J.P. Morgan Maintains DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Raises Target Price to $47.41
Merck, Daiichi Sankyo Expand Cancer Drug Deal
Daiichi Sankyo Non-GAAP EPS of Yen 44.57, Revenue of Yen 436.19B
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
DAIICHI SANKYO COMPANY LIMITED To Go Ex-Dividend On September 27th, 2024 With 0.264 USD Dividend Per Share
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Merck, Daiichi Lung Cancer Therapy Rejected in U.S.
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Daiichi Sankyo/AstraZeneca (AZN.US) launches phase III clinical first-line treatment for EGFR mutation NSCLC in China
On May 27, according to the CDE clinical trial registration and information disclosure platform, Daiichi Sanko/AstraZeneca (AZN.US) registered on the platform to launch a new phase III clinical tropion-Lung14 study with dATO-DXD (DS-1062A/dedabotumab) to first-line treatment of patients with locally advanced or metastatic NSCLC positive EGFR mutations (registration number: CTR20241813).
The backstage Nikkei Average started with 119 yen depreciation, and Daiichi Sankyo, Nintendo, etc. fell
[Nikkei Stock Average, TOPIX (table)] Nikkei Average; 38780.55; -119.47TOPIX; 2762.23; -4.13 [Backward Closer Overview] The Nikkei Average in the back was 38780.55 yen, 119.47 yen lower than the previous day, and started at almost the same level as the advance draw (38783.27 yen). Nikkei 225 futures during lunchtime fit well in the 38760 yen to 38840 yen range. Dollar/yen is 1 dollar = 156.60-70 yen, and yen appreciates by about 20 yen from around 9:00 a.m.
AstraZeneca, Daiichi Sankyo's Lung Cancer Drug Shows Mixed Results in Late-stage Trial
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Double Good News For AstraZeneca's Breast Cancer Drugs
Express News | Daiichi Sankyo And AstraZeneca's Shows Statistically Significant And Clinically Meaningful Improvement In HR+, HER2 Low Breast Cancer: DESTINY-Breast06 Trial Results
Earnings Call Summary | DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) Q4 2023 Earnings Conference
The Nikkei Average in the backstage started with a 297 yen increase, and Daiichi Sankyo and Mitsui E&S are high
[Nikkei Stock Average, TOPIX (table)] Nikkei Average; 37926.06; +297.58TOPIX; 2681.69; +18.16 [Backward Closer Overview] The Nikkei Average in the back was 37926.06 yen, 297.58 yen higher than the previous day, and started by expanding the range of gains from the previous closing (37780.35 yen). Nikkei 225 futures during lunchtime rose in the range of 37740 yen to 38,000 yen. The dollar and yen depreciated by about 40 yen from around 9:00 a.m. to 1 dollar = 156.00-10 yen
No Data